Oncostatin M receptor Β and cysteine/histidine-rich 1 are biomarkers of the response to erythropoietin in hemodialysis patients

Kidney International

Volumn 79, Issue 5, 2011, Pages 546-554

  Merchant, Michael L ^a   Gaweda, Adam E ^a   Dailey, Andrew J ^a,b   Wilkey, Daniel W ^a   Zhang, Xiaolan ^c   Rovin, Brad H ^c   Klein, Jon B ^a,b   Brier, Michael E ^a,b  

^a University of Louisville School of Medicine   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

anemia; biomarker; erythropoietic; hemodialysis; peptidomics

Indexed keywords

BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 13A; COMPLEMENT COMPONENT C3; CYSTEINE; CYSTEINE HISTIDINE RICH 1; ERYTHROPOIETIN; FIBRINOGEN; FIBRINOGEN ALPHA; FIBRINOGEN BETA; HISTIDINE; ONCOSTATIN M RECEPTOR BETA; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; CLINICAL ARTICLE; FEMALE; HEMODIALYSIS PATIENT; HUMAN; MALE; MASS SPECTROMETRY; PEPTIDOMICS; PRIORITY JOURNAL;

EID: 79951638237     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.468     Document Type: Article

References (30)

1. Zhang Y, Thamer M, Stefanik K et al. Epoetin requirement predict mortality in hemodialysis patients. Am J Kidney Dis 2004; 44: 866-876. (Pubitemid 39445919)
2. Szczech LA, Barnhart HX, Inrig JK et al. Secondary analysis of the CHOIR trial epoetin - a dose and achieved hemoglobin outcomes. Kidney Int 2008; 74: 791-798.
3. Macdougall IC, Cooper AC Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines. Nephrol Dial Transplant 2002; 17(Suppl 11): 39-43.
4. Johnson DW, Pollock CA, Macdougall IC. Erythropoiesis-stimulating agents hyporesponsiveness. Nephrology 2007; 12: 321-330.
5. Danielson B. R-HuEPO hyporesponsiveness\who and why? Nephrol Dial Transplant 1995; 10: 69-73.
6. Peces R, de la Torre M, Alcázar R et al. Antibodies against recombinant human erythropoietin in a patient with erythropoietin-resistant anemia. N Engl J Med 1996; 335: 523-524. (Pubitemid 26269960)
7. Goicoechea M, Martin J, de Sequera P et al. Role of cytokines in the response to erythropoietin in hemodialysis patients. Kidney Int 1998; 54: 1337-1343. (Pubitemid 28449924)
8. Van der Putten K, Braam B, Jie KE et al. Mechanisms of disease: erythropoietin resistance in patients with both heart and kidney failure. Nat Clin Pract Nephrol 2008; 4: 47-57. (Pubitemid 350308210)
9. Nemeth E, Rivera S, Gabayan V et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004; 113: 1271-1276. (Pubitemid 39069926)
10. Andrews NC. Anemia of inflammation: the cytokine-hepcidin link. J Clin Invest 2004; 113: 1251-1253. (Pubitemid 39069921)
11. Khankin EV, Mutter WP, Tamez H et al. Soluble erythropoietin receptor contributes to erythropoietin resistance in end-stage renal disease. PLoS One 2010; 16: e9246.
12. Inrig JK, Patel U, Bryskin S et al. Association between high-dose ESA, inflammatory biomarkers, and soluble erythropoietin receptors. J Am Soc Nephrol 2009; 20: 143A.
13. Mann M, Kelleher NL Precision proteomics: the case for high resolution and high mass accuracy. Proc Natl Acad Sci USA 2008; 105: 18132-18138.
14. Matthews V, Schuster B, Schütze S et al. Cellular cholesterol depletion triggers shedding of the human interleukin-6 receptor by ADAM10 and ADAM17 (TACE). J Biol Chem 2003; 278: 38829-38839. (Pubitemid 37221782)
15. Chen D, Chu CY, Chen CY et al. Expression of short-form oncostatin M receptor as a decoy receptor in lung adenocarcinomas. J Pathol 2008; 215: 290-299. (Pubitemid 351956710)
16. Tanka M, Hirgayashi Y, Sekiguchi T et al. Targeted disruption of oncostatin M receptor results in altered hematopoiesis. Blood 2003; 102: 3154-3162. (Pubitemid 37314751)
17. Menon MP, Karur V, Bogacheva O et al. Signals for stress erythropoiesis are integrated via and erythropoietin receptor-phosphotyrosine-343-Stat5 axis. J Clin Invest 2006; 116: 683-694. (Pubitemid 43326877)
18. Brown TJ, Lioubin MN, Marquardt H. Purification and characterization of cytostatic lymphokines produced by activated human T lymphocytes: synergistic antiproliferative activity of transforming growth factor beta 1, interferon-gamma, and oncostatin M for human melanoma cells. J Immunol 1987; 139: 2977-2983. (Pubitemid 17157467)
19. Malik N, Kallestad JC, Gunderson NL et al. Molecular cloning, sequence analysis, and functional expression of a novel growth regulator, oncostatin M. Mol Cell Biol 1989; 9: 2847-2853. (Pubitemid 19163046)
20. Thoma B, Bird TA, Friend DJ et al. Oncostatin M and leukemia inhibitory factor trigger overlapping and different signals through partially shared receptor complexes. J Biol Chem 1994; 269: 6215-6222. (Pubitemid 24243012)
21. Mosley B, De Imus C, Friend D et al. Dual oncostatin M (OSM) receptors. Cloning and characterization of an alternative signaling subunit conferring OSM-specific receptor activation. J Biol Chem 1996; 271: 32635-32643. (Pubitemid 27008685)
22. Blanchard F, Wang Y, Kinzie E et al. Oncostatin M regulates the synthesis and turnover of gp130, leukemia inhibitory factor receptor a, and oncostatin M receptor b by distinct mechanisms. J Biol Chem 2001; 50: 47038-47045.
23. Vollner S, Kappler V, Kaczor J et al. Hypoxia-inducible factor 1a is up-regulated by oncostatin M and participates in oncostatin M signaling. Hepatology 2009; 50: 253-260.
24. Menon RP, Strom M, Hughes RC. Interaction of a novel cysteine and histidine-rich cytoplasmic protein with galectin-3 in a carbohydrate-independent manner. FEBS Lett 2000; 470: 227-231. (Pubitemid 30169269)
25. Bawumia S, Barboni EAM, Menon RP et al. Specificity of interactions of galectin-3 with Chrp a cysteine-and histidine-rich cytoplasmic protein. Biochimie 2003; 85: 189-194. (Pubitemid 36625993)
26. Kaysen GA. The microinflammatory state in uremia: causes and potential consequences. J Am Soc Nephrol 2001; 12: 1549-1557. (Pubitemid 32666340)
27. Narayanan S. Multifunctional roles of thrombin. Ann Clin Lab Sci 1999; 29: 275-280. (Pubitemid 29505961)
28. Borawski J, Pawlak K, oelig;liwiec M. Inflammatory markers and platelet aggregation tests as predictors of hemoglobin and endogenous erythropoietin levels in hemodialysis patients. Nephron 2002; 91: 671-681. (Pubitemid 34914070)
29. Merchant ML, Perkins BA, Boratyn GM et al. Urinary peptidome may predict renal function decline in type 1 diabetes and microalbuminuria. J Am Soc Nephrol 2009; 20: 2065-2074.
30. Merchant ML, Cummins TD, Wilkey DW et al. Proteomic analysis of renal calculi indicates an important role for inflammatory processes in calcium stone formation. Am J Physiol Renal Physiol 2008; 295: F1254-F1258.